

## The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism

Tamer Shalaby,<sup>1</sup> Samantha Anandappa,<sup>2</sup> Siva Sivappriyan<sup>3</sup> and Jesse Kumar<sup>3</sup>

1. Registrar in Acute Medicine and Endocrinology; 2. CT1 Endocrinology; 3. Consultant Endocrinologist, Maidstone Hospital, Maidstone, Kent, UK

**Citation:** *European Endocrinology*, 2015;11(1):xi[online only]

**Erratum to:** *European Endocrinology*, 2014;10(2):151–2

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section of the above-mentioned paper: All procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions. Informed consent was received from the patient involved in this case study.